GreenLight Biosciences Holdings PBC

GreenLight Biosciences is a biotechnology company specializing in the design and manufacture of RNA-based solutions for human health and agriculture. The company utilizes a proprietary cell-free RNA manufacturing platform that allows for the scalable and cost-effective production of high-quality mRNA and dsRNA. In human health, GreenLight focuses on developing mRNA vaccines and therapeutics for infectious diseases, including COVID-19 and shingles. Its agricultural division develops targeted RNA-based biopesticides, such as Calantha, to protect crops and honeybees without the environmental impact of traditional chemicals. The company was acquired by a consortium led by Fall Line Capital in 2023, transitioning from a public to a private entity.